Cat. No. Name Size Price Add Cart
KI1228Givinostat5 mg$272
Givinostat10 mg$512
Givinostat50 mg$1552
Givinostat200 mg$3952

Chemical Characteristic

Product NameGivinostat
SynonymsITF2357
CAS No.732302-99-7
Molecular Weight 475.97
FormulaC24H27N3O4.HCl.H2O
Chemical Namediethyl-[[6-[[4-(hydroxycarbamoyl)phenyl]carbamoyloxymethyl]naphthalen-2-yl]methyl]azanium;chloride;hydrate
SmilesC(=O)(Nc1ccc(cc1)C(=O)NO)OCc1cc2c(cc1)cc(cc2)CN(CC)CC Cl O
Chemical Structure

Biological activities

Givinostat is a potent inhibitor of HDAC with IC50 values of 10, 7.5 and 16 nM for HD2, HD1-B and HD1-A, respectively. In lipopolysaccharide (LPS)-stimulated cultured human peripheral blood mononuclear cells (PBMCs), givinostat reduces the releases of tumor necrosis factor-α (TNFα), intracellular interleukin (IL)-1α, IL-1β, and interferon-γ (IFNγ) with IC50 values ranging from 10 to 25 nM. Using the combination of IL-12 plus IL-18, givinostat reduces IFNγ and IL-6 production by 50% at 12.5 to 25 nM, independent of decreased IL-1 or TNFα.[1] In vitro, givinostat induces apoptosis in multiple myeloma (MM) cell lines (including RPMI8226, NCI-H929, JJN3 and KMS 11) and acute myelogenous leukemia (AML) cell lines (including HL-60, THP-1, U937 and KASUMI) with a mean IC50 value of 200 nM. In more physiological conditions, givinostat is still strongly cytotoxic for the IL-6-dependent MM cell line CMA-03, or for AML samples maximally stimulated by co-culture on mesenchymal stromal cells (MSCs), but not for the MSCs themselves.[2] Oral administration of givinostat (1 to 10 mg/kg) to mice reduces LPS-induced serum TNFα and IFNγ by more than 50%.[1] Givinostat (10 mg/kg) significantly prolongs survival of severe combined immunodeficient mice inoculated with the AML-PS in vivo passaged cell line.[2] In mice normalized streptozotocin-induced hyperglycemia, givinostat (1.25-2.5 mg/kg) returns serum nitrite levels to nondiabetic values, improves islet function and increases glucose clearance from 14% to 50%.[3]

Protocols

In vivo: Givinostat is added to water and heated to 90 °C until dissolved.[1]

References

[1] Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005, 11(1-12): 1-15.
[2] Golay J, et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 2007, 21(9): 1892-1900.
[3] Eli C Lewis, et al. The Oral Histone Deacetylase Inhibitor ITF2357 Reduces Cytokines and Protects Islet β Cells In Vivo and In Vitro. Mol Med. 2011, 17(5-6): 369-377.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.